Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Drug repositioning is the process of identifying new indications for existing drugs. At present, the conventional de novo drug discovery process requires an average of about 14 years and US$2.5 billion to approve and launch a drug. Drug repositioning can reduce the time and cost of this process because it takes advantage of drugs already in clinical use for other indications or drugs that have cleared phase I safety trials but have failed to show efficacy in the intended diseases. Historically, drug repositioning has been realized through serendipitous clinical observations or improved understanding of disease mechanisms. However, recent technological advances have enabled a more systematic approach to drug repositioning. This eBook collects 16 articles from 112 authors, providing readers with current advances and future perspectives of drug repositioning.

database --- Integrative strategies --- molecular docking --- polypharmacology --- multi-omics --- computational analysis --- Drug Repositioning --- data sharing --- Patenting

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Drug repositioning is the process of identifying new indications for existing drugs. At present, the conventional de novo drug discovery process requires an average of about 14 years and US$2.5 billion to approve and launch a drug. Drug repositioning can reduce the time and cost of this process because it takes advantage of drugs already in clinical use for other indications or drugs that have cleared phase I safety trials but have failed to show efficacy in the intended diseases. Historically, drug repositioning has been realized through serendipitous clinical observations or improved understanding of disease mechanisms. However, recent technological advances have enabled a more systematic approach to drug repositioning. This eBook collects 16 articles from 112 authors, providing readers with current advances and future perspectives of drug repositioning.

database --- Integrative strategies --- molecular docking --- polypharmacology --- multi-omics --- computational analysis --- Drug Repositioning --- data sharing --- Patenting

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

China plays a variety of status games, sometimes emphasizing its status as an emerging great power and other times highlighting its status as a fragile developing country. The reasons for this are unclear. Drawing on original Chinese sources, social psychological theories, and international relations theories, this text provides a theoretically informed analysis of China's global rebranding and repositioning in the twenty-first century.

Diplomatic relations. --- China --- Foreign relations --- S09/0264 --- China: Foreign relations and world politics--General works: since 1989 --- China. --- audience. --- diplomacy. --- foreign policy. --- image. --- international relations theory. --- rebranding. --- repositioning. --- status signaling. --- status.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The discovery of new drugs is one of pharmaceutical research's most exciting and challenging tasks. Unfortunately, the conventional drug discovery procedure is chronophagous and seldom successful; furthermore, new drugs are needed to address our clinical challenges (e.g., new antibiotics, new anticancer drugs, new antivirals).Within this framework, drug repositioning—finding new pharmacodynamic properties for already approved drugs—becomes a worthy drug discovery strategy.Recent drug discovery techniques combine traditional tools with in silico strategies to identify previously unaccounted properties for drugs already in use. Indeed, big data exploration techniques capitalize on the ever-growing knowledge of drugs' structural and physicochemical properties, drug–target and drug–drug interactions, advances in human biochemistry, and the latest molecular and cellular biology discoveries.Following this new and exciting trend, this book is a collection of papers introducing innovative computational methods to identify potential candidates for drug repositioning. Thus, the papers in the Special Issue In Silico Strategies for Prospective Drug Repositionings introduce a wide array of in silico strategies such as complex network analysis, big data, machine learning, molecular docking, molecular dynamics simulation, and QSAR; these strategies target diverse diseases and medical conditions: COVID-19 and post-COVID-19 pulmonary fibrosis, non-small lung cancer, multiple sclerosis, toxoplasmosis, psychiatric disorders, or skin conditions.

Medicine --- Pharmaceutical industries --- COVID-19 --- drug repurposing --- topological data analysis --- persistent Betti function --- SARS-CoV-2 --- network-based pharmacology --- combination therapy --- nucleoside GS-441524 --- fluoxetine --- synergy --- antidepressant --- natural compounds --- QSAR --- molecular docking --- drug repositioning --- UK Biobank --- vaccine --- LC-2/ad cell line --- drug discovery --- docking --- MM-GBSA calculation --- molecular dynamics --- cytotoxicity assay --- GWAS --- multiple sclerosis --- oxidative stress --- repurposing --- ADME-Tox --- bioinformatics --- complex network analysis --- modularity clustering --- ATC code --- hidradenitis suppurativa --- acne inversa --- transcriptome --- proteome --- comorbid disorder --- biomarker --- signaling pathway --- druggable gene --- drug-repositioning --- MEK inhibitor --- MM/GBSA --- Glide docking --- MD simulation --- MM/PBSA --- single-cell RNA sequencing --- pulmonary fibrosis --- biological networks --- p38α MAPK --- allosteric inhibitors --- in silico screening --- computer-aided drug discovery --- network analysis --- psychiatric disorders --- medications --- psychiatry --- mental disorders --- toxoplasmosis --- Toxoplasma gondii --- in vitro screening --- drug targets --- drug-disease interaction --- target-disease interaction --- DPP4 inhibitors --- lipid rafts

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"Drug Repurposing in Cancer Therapy: Approaches and Applications provides comprehensive and updated information from experts in basic science research and clinical practice on how existing drugs can be repurposed for cancer treatment. The book summarizes successful stories that may assist researchers in the field to better design their studies for new repurposing projects. Sections discuss specific topics such as in silico prediction and high throughput screening of repurposed drugs, drug repurposing for overcoming chemoresistance and eradicating cancer stem cells, and clinical investigation on combination of repurposed drug and anticancer therapy"--Publisher's description.

Cancer --- Off-label drug use. --- Drug Repositioning --- Neoplasms --- Off-Label Use --- Chemotherapy. --- methods --- drug therapyd0http://id.nlm.nih.gov/mesh/D009369Q000188. --- Off-Label Use. --- methods. --- drug therapy. --- Antineoplastic agents --- Treatment --- Extra-label drug use --- Off-label prescribing --- Drug utilization --- Drugs --- Prescribing --- Dose-Sparing Drug Use --- Fractional Dose Drug Use --- Off-Label Prescribing --- Reduced-Dose Drug Use --- Unlabeled Indication --- Dose Sparing Drug Use --- Dose-Sparing Drug Uses --- Indication, Unlabeled --- Off Label Prescribing --- Off Label Use --- Off-Label Prescribings --- Off-Label Uses --- Prescribing, Off-Label --- Reduced Dose Drug Use --- Reduced-Dose Drug Uses --- Unlabeled Indications --- Drug Labeling